Intravenous	B:C0085297
and	O
subcutaneous	O
immunoglobulin	O
G	I:C0020852
replacement	O
therapy	I:C0279033
.	O

Intravenous	O
and	O
subcutaneous	O
immunoglobulin	B:C0020852
G	I:C0020852
replacement	O
therapy	I:C0279033
.	O

Intravenous	O
and	O
subcutaneous	O
immunoglobulin	O
G	I:C0020852
replacement	B:C0279033
therapy	I:C0279033
.	O

Human	B:C0086418
polyclonal	O
immunoglobulin	O
G	I:C0020852
(	O
immunoglobulin	O
G	I:C0020852
)	O
for	O
therapeutic	O
use	O
has	O
been	O
available	O
for	O
decades	O
.	O

Human	O
polyclonal	B:C0312586
immunoglobulin	O
G	I:C0020852
(	O
immunoglobulin	O
G	I:C0020852
)	O
for	O
therapeutic	O
use	O
has	O
been	O
available	O
for	O
decades	O
.	O

Human	O
polyclonal	O
immunoglobulin	B:C0020852
G	I:C0020852
(	O
immunoglobulin	O
G	I:C0020852
)	O
for	O
therapeutic	O
use	O
has	O
been	O
available	O
for	O
decades	O
.	O

Human	O
polyclonal	O
immunoglobulin	O
G	I:C0020852
(	O
immunoglobulin	B:C0020852
G	I:C0020852
)	O
for	O
therapeutic	O
use	O
has	O
been	O
available	O
for	O
decades	O
.	O

This	O
drug	B:C1254351
was	O
developed	O
for	O
treatment	O
of	O
antibody	O
deficiency	I:C0003257
(	O
replacement	O
therapy	I:C0279033
)	O
,	O
although	O
its	O
use	O
has	O
expanded	O
into	O
many	O
anti-inflammatory	O
and	O
immunomodulatory	O
applications	O
in	O
recent	O
years	O
.	O

This	O
drug	O
was	O
developed	O
for	O
treatment	O
of	O
antibody	B:C0003257
deficiency	I:C0003257
(	O
replacement	O
therapy	I:C0279033
)	O
,	O
although	O
its	O
use	O
has	O
expanded	O
into	O
many	O
anti-inflammatory	O
and	O
immunomodulatory	O
applications	O
in	O
recent	O
years	O
.	O

This	O
drug	O
was	O
developed	O
for	O
treatment	O
of	O
antibody	O
deficiency	I:C0003257
(	O
replacement	B:C0279033
therapy	I:C0279033
)	O
,	O
although	O
its	O
use	O
has	O
expanded	O
into	O
many	O
anti-inflammatory	O
and	O
immunomodulatory	O
applications	O
in	O
recent	O
years	O
.	O

This	O
drug	O
was	O
developed	O
for	O
treatment	O
of	O
antibody	O
deficiency	I:C0003257
(	O
replacement	O
therapy	I:C0279033
)	O
,	O
although	O
its	O
use	O
has	O
expanded	O
into	O
many	O
anti-inflammatory	O
and	O
immunomodulatory	B:C1963758
applications	O
in	O
recent	O
years	O
.	O

This	O
review	B:C0282443
focuses	O
on	O
immunoglobulin	O
G	I:C0020852
prescribing	O
for	O
replacement	O
therapy	I:C0279033
.	O

This	O
review	O
focuses	O
on	O
immunoglobulin	B:C0020852
G	I:C0020852
prescribing	O
for	O
replacement	O
therapy	I:C0279033
.	O

This	O
review	O
focuses	O
on	O
immunoglobulin	O
G	I:C0020852
prescribing	O
for	O
replacement	B:C0279033
therapy	I:C0279033
.	O

immunoglobulin	B:C0020852

G	I:C0020852
for	O
replacement	B:C0279033
is	O
most	O
often	O
administered	O
via	O
the	O
intravenous	O
IgG	I:C0020852
(	O
intravenous	O
IgG	I:C0020852
)	O
or	O
subcutaneous	O
IgG	I:C0020852
(	O
subcutaneous	O
IgG	I:C0020852
)	O
routes	O
.	O

G	I:C0020852
for	O
replacement	O
is	O
most	O
often	O
administered	O
via	O
the	O
intravenous	B:C0020852
IgG	I:C0020852
(	O
intravenous	O
IgG	I:C0020852
)	O
or	O
subcutaneous	O
IgG	I:C0020852
(	O
subcutaneous	O
IgG	I:C0020852
)	O
routes	O
.	O

G	I:C0020852
for	O
replacement	O
is	O
most	O
often	O
administered	O
via	O
the	O
intravenous	O
IgG	I:C0020852
(	O
intravenous	B:C0020852
IgG	I:C0020852
)	O
or	O
subcutaneous	O
IgG	I:C0020852
(	O
subcutaneous	O
IgG	I:C0020852
)	O
routes	O
.	O

G	I:C0020852
for	O
replacement	O
is	O
most	O
often	O
administered	O
via	O
the	O
intravenous	O
IgG	I:C0020852
(	O
intravenous	O
IgG	I:C0020852
)	O
or	O
subcutaneous	B:C0020852
IgG	I:C0020852
(	O
subcutaneous	O
IgG	I:C0020852
)	O
routes	O
.	O

G	I:C0020852
for	O
replacement	O
is	O
most	O
often	O
administered	O
via	O
the	O
intravenous	O
IgG	I:C0020852
(	O
intravenous	O
IgG	I:C0020852
)	O
or	O
subcutaneous	O
IgG	I:C0020852
(	O
subcutaneous	B:C0020852
IgG	I:C0020852
)	O
routes	O
.	O

intravenous	B:C0020852
IgG	I:C0020852
is	O
usually	O
administered	O
every	O
34	O
weeks	O
,	O
and	O
subcutaneous	O
IgG	I:C0020852
is	O
usually	O
administered	O
weekly	O
,	O
although	O
variations	O
may	O
be	O
considered	O
in	O
all	O
cases	O
.	O

intravenous	O
IgG	I:C0020852
is	O
usually	O
administered	O
every	O
34	O
weeks	O
,	O
and	O
subcutaneous	B:C0020852
IgG	I:C0020852
is	O
usually	O
administered	O
weekly	O
,	O
although	O
variations	O
may	O
be	O
considered	O
in	O
all	O
cases	O
.	O

Recently	O
,	O
a	O
new	B:C1254351
product	I:C1254351
became	O
available	O
that	O
uses	O
hyaluronidase	O
to	O
facilitate	O
absorption	O
of	O
large	O
doses	O
of	O
subcutaneous	O
IgG	I:C0020852
less	O
frequently	O
(	O
every	O
34	O
weeks	O
,	O
as	O
with	O
intravenous	O
IgG	I:C0020852
)	O
.	O

Recently	O
,	O
a	O
new	O
product	I:C1254351
became	O
available	O
that	O
uses	O
hyaluronidase	B:C0020197
to	O
facilitate	O
absorption	O
of	O
large	O
doses	O
of	O
subcutaneous	O
IgG	I:C0020852
less	O
frequently	O
(	O
every	O
34	O
weeks	O
,	O
as	O
with	O
intravenous	O
IgG	I:C0020852
)	O
.	O

Recently	O
,	O
a	O
new	O
product	I:C1254351
became	O
available	O
that	O
uses	O
hyaluronidase	O
to	O
facilitate	O
absorption	O
of	O
large	O
doses	O
of	O
subcutaneous	B:C0020852
IgG	I:C0020852
less	O
frequently	O
(	O
every	O
34	O
weeks	O
,	O
as	O
with	O
intravenous	O
IgG	I:C0020852
)	O
.	O

Recently	O
,	O
a	O
new	O
product	I:C1254351
became	O
available	O
that	O
uses	O
hyaluronidase	O
to	O
facilitate	O
absorption	O
of	O
large	O
doses	O
of	O
subcutaneous	O
IgG	I:C0020852
less	O
frequently	O
(	O
every	O
34	O
weeks	O
,	O
as	O
with	O
intravenous	B:C0020852
IgG	I:C0020852
)	O
.	O

intravenous	B:C0020852
IgG	I:C0020852
therapy	O
leads	O
to	O
high	O
peaks	O
and	O
low	O
troughs	O
between	O
infusions	O
.	O

intravenous	O
IgG	I:C0020852
therapy	B:C0279033
leads	O
to	O
high	O
peaks	O
and	O
low	O
troughs	O
between	O
infusions	O
.	O

intravenous	O
IgG	I:C0020852
therapy	O
leads	O
to	O
high	O
peaks	O
and	O
low	O
troughs	O
between	O
infusions	B:C0574032
.	O

immunoglobulin	B:C0020852
G	I:C0020852
concentration	O
fluctuates	O
much	O
less	O
over	O
time	O
with	O
subcutaneous	O
IgG.	I:C0020852
Hyaluronidase	O
-	O
facilitated	O
subcutaneous	O
IgG	I:C0020852
is	O
intermediate	O
.	O

immunoglobulin	O
G	I:C0020852
concentration	O
fluctuates	O
much	O
less	O
over	O
time	O
with	O
subcutaneous	B:C0020852
IgG.	I:C0020852
Hyaluronidase	O
-	O
facilitated	O
subcutaneous	O
IgG	I:C0020852
is	O
intermediate	O
.	O

immunoglobulin	O
G	I:C0020852
concentration	O
fluctuates	O
much	O
less	O
over	O
time	O
with	O
subcutaneous	O
IgG.	I:C0020852
Hyaluronidase	B:C0020197
-	O
facilitated	O
subcutaneous	O
IgG	I:C0020852
is	O
intermediate	O
.	O

immunoglobulin	O
G	I:C0020852
concentration	O
fluctuates	O
much	O
less	O
over	O
time	O
with	O
subcutaneous	O
IgG.	I:C0020852
Hyaluronidase	O
-	O
facilitated	O
subcutaneous	B:C0020852
IgG	I:C0020852
is	O
intermediate	O
.	O

subcutaneous	B:C0020852
IgG	I:C0020852
may	O
have	O
lower	O
bioavailability	O
in	O
comparison	O
with	O
intravenous	O
IgG	I:C0020852
and	O
may	O
require	O
higher	O
doses	O
over	O
time	O
;	O
this	O
is	O
not	O
true	O
for	O
hyaluronidase	O
subcutaneous	O
IgG	I:C0020852
.	O

subcutaneous	O
IgG	I:C0020852
may	O
have	O
lower	O
bioavailability	O
in	O
comparison	O
with	O
intravenous	B:C0020852
IgG	I:C0020852
and	O
may	O
require	O
higher	O
doses	O
over	O
time	O
;	O
this	O
is	O
not	O
true	O
for	O
hyaluronidase	O
subcutaneous	O
IgG	I:C0020852
.	O

subcutaneous	O
IgG	I:C0020852
may	O
have	O
lower	O
bioavailability	O
in	O
comparison	O
with	O
intravenous	O
IgG	I:C0020852
and	O
may	O
require	O
higher	O
doses	O
over	O
time	O
;	O
this	O
is	O
not	O
true	O
for	O
hyaluronidase	B:C0020197
subcutaneous	O
IgG	I:C0020852
.	O

subcutaneous	O
IgG	I:C0020852
may	O
have	O
lower	O
bioavailability	O
in	O
comparison	O
with	O
intravenous	O
IgG	I:C0020852
and	O
may	O
require	O
higher	O
doses	O
over	O
time	O
;	O
this	O
is	O
not	O
true	O
for	O
hyaluronidase	O
subcutaneous	B:C0020852
IgG	I:C0020852
.	O

However	O
,	O
there	O
are	O
large	O
variations	O
in	O
immunoglobulin	B:C0020852
G	I:C0020852
half	O
-	O
life	O
among	O
individuals	O
and	O
with	O
different	O
products	O
.	O

However	O
,	O
there	O
are	O
large	O
variations	O
in	O
immunoglobulin	O
G	I:C0020852
half	O
-	O
life	O
among	O
individuals	B:C0237401
and	O
with	O
different	O
products	O
.	O

Therefore	O
,	O
individualization	O
of	O
therapy	B:C0279033
is	O
essential	O
.	O

Mild	O
systemic	O
flu	B:C0879626
-	I:C0879626
like	I:C0879626
adverse	I:C0879626
effects	I:C0879626
may	O
affect	O
up	O
to	O
2025	O
%	O
of	O
patients	O
who	O
receive	O
intravenous	O
IgG	I:C0020852
,	O
smaller	O
fractions	O
may	O
experience	O
more	O
-	O
severe	O
symptoms	O
,	O
whereas	O
anaphylaxis	O
is	O
exceedingly	O
rare	O
.	O

Mild	O
systemic	O
flu	O
-	I:C0879626
like	I:C0879626
adverse	I:C0879626
effects	I:C0879626
may	O
affect	O
up	O
to	O
2025	O
%	O
of	O
patients	O
who	O
receive	O
intravenous	B:C0020852
IgG	I:C0020852
,	O
smaller	O
fractions	O
may	O
experience	O
more	O
-	O
severe	O
symptoms	O
,	O
whereas	O
anaphylaxis	O
is	O
exceedingly	O
rare	O
.	O

Mild	O
systemic	O
flu	O
-	I:C0879626
like	I:C0879626
adverse	I:C0879626
effects	I:C0879626
may	O
affect	O
up	O
to	O
2025	O
%	O
of	O
patients	O
who	O
receive	O
intravenous	O
IgG	I:C0020852
,	O
smaller	O
fractions	O
may	O
experience	O
more	O
-	O
severe	O
symptoms	O
,	O
whereas	O
anaphylaxis	B:C0002792
is	O
exceedingly	O
rare	O
.	O

General	O
flu	B:C0879626
-	I:C0879626
like	I:C0879626
systemic	I:C0879626
adverse	I:C0879626
effects	I:C0879626
are	O
minimal	O
with	O
subcutaneous	O
IgG	I:C0020852
(	O
intermediate	O
with	O
hyaluronidase	O
subcutaneous	O
IgG	I:C0020852
)	O
,	O
but	O
transient	O
(	O
24	O
hours	O
)	O
,	O
mild	O
,	O
local	O
inflammatory	O
symptoms	I:C1457887
at	O
infusion	O
sites	I:C2697750
are	O
relatively	O
common	O
with	O
both	O
forms	O
.	O

General	O
flu	O
-	I:C0879626
like	I:C0879626
systemic	I:C0879626
adverse	I:C0879626
effects	I:C0879626
are	O
minimal	O
with	O
subcutaneous	B:C0020852
IgG	I:C0020852
(	O
intermediate	O
with	O
hyaluronidase	O
subcutaneous	O
IgG	I:C0020852
)	O
,	O
but	O
transient	O
(	O
24	O
hours	O
)	O
,	O
mild	O
,	O
local	O
inflammatory	O
symptoms	I:C1457887
at	O
infusion	O
sites	I:C2697750
are	O
relatively	O
common	O
with	O
both	O
forms	O
.	O

General	O
flu	O
-	I:C0879626
like	I:C0879626
systemic	I:C0879626
adverse	I:C0879626
effects	I:C0879626
are	O
minimal	O
with	O
subcutaneous	O
IgG	I:C0020852
(	O
intermediate	O
with	O
hyaluronidase	B:C0020197
subcutaneous	O
IgG	I:C0020852
)	O
,	O
but	O
transient	O
(	O
24	O
hours	O
)	O
,	O
mild	O
,	O
local	O
inflammatory	O
symptoms	I:C1457887
at	O
infusion	O
sites	I:C2697750
are	O
relatively	O
common	O
with	O
both	O
forms	O
.	O

General	O
flu	O
-	I:C0879626
like	I:C0879626
systemic	I:C0879626
adverse	I:C0879626
effects	I:C0879626
are	O
minimal	O
with	O
subcutaneous	O
IgG	I:C0020852
(	O
intermediate	O
with	O
hyaluronidase	O
subcutaneous	B:C0020852
IgG	I:C0020852
)	O
,	O
but	O
transient	O
(	O
24	O
hours	O
)	O
,	O
mild	O
,	O
local	O
inflammatory	O
symptoms	I:C1457887
at	O
infusion	O
sites	I:C2697750
are	O
relatively	O
common	O
with	O
both	O
forms	O
.	O

General	O
flu	O
-	I:C0879626
like	I:C0879626
systemic	I:C0879626
adverse	I:C0879626
effects	I:C0879626
are	O
minimal	O
with	O
subcutaneous	O
IgG	I:C0020852
(	O
intermediate	O
with	O
hyaluronidase	O
subcutaneous	O
IgG	I:C0020852
)	O
,	O
but	O
transient	O
(	O
24	O
hours	O
)	O
,	O
mild	O
,	O
local	O
inflammatory	B:C1457887
symptoms	I:C1457887
at	O
infusion	O
sites	I:C2697750
are	O
relatively	O
common	O
with	O
both	O
forms	O
.	O

General	O
flu	O
-	I:C0879626
like	I:C0879626
systemic	I:C0879626
adverse	I:C0879626
effects	I:C0879626
are	O
minimal	O
with	O
subcutaneous	O
IgG	I:C0020852
(	O
intermediate	O
with	O
hyaluronidase	O
subcutaneous	O
IgG	I:C0020852
)	O
,	O
but	O
transient	O
(	O
24	O
hours	O
)	O
,	O
mild	O
,	O
local	O
inflammatory	O
symptoms	I:C1457887
at	O
infusion	B:C2697750
sites	I:C2697750
are	O
relatively	O
common	O
with	O
both	O
forms	O
.	O

Additional	O
rare	O
but	O
important	O
complications	B:C0009566
of	O
immunoglobulin	O
G	I:C0020852
therapy	O
include	O
thrombotic	O
events	I:C0040053
and	O
hemolysis	O
that	O
can	O
be	O
seen	O
at	O
high	O
doses	O
with	O
any	O
route	O
of	O
administration	O
.	O

Additional	O
rare	O
but	O
important	O
complications	O
of	O
immunoglobulin	B:C0020852
G	I:C0020852
therapy	O
include	O
thrombotic	O
events	I:C0040053
and	O
hemolysis	O
that	O
can	O
be	O
seen	O
at	O
high	O
doses	O
with	O
any	O
route	O
of	O
administration	O
.	O

Additional	O
rare	O
but	O
important	O
complications	O
of	O
immunoglobulin	O
G	I:C0020852
therapy	B:C0279033
include	O
thrombotic	O
events	I:C0040053
and	O
hemolysis	O
that	O
can	O
be	O
seen	O
at	O
high	O
doses	O
with	O
any	O
route	O
of	O
administration	O
.	O

Additional	O
rare	O
but	O
important	O
complications	O
of	O
immunoglobulin	O
G	I:C0020852
therapy	O
include	O
thrombotic	B:C0040053
events	I:C0040053
and	O
hemolysis	O
that	O
can	O
be	O
seen	O
at	O
high	O
doses	O
with	O
any	O
route	O
of	O
administration	O
.	O

Additional	O
rare	O
but	O
important	O
complications	O
of	O
immunoglobulin	O
G	I:C0020852
therapy	O
include	O
thrombotic	O
events	I:C0040053
and	O
hemolysis	B:C0019054
that	O
can	O
be	O
seen	O
at	O
high	O
doses	O
with	O
any	O
route	O
of	O
administration	O
.	O

Renal	B:C0022646
adverse	O
effects	I:C0879626
may	O
occur	O
with	O
intravenous	O
IgG	I:C0020852
as	O
well	O
.	O

Renal	O
adverse	B:C0879626
effects	I:C0879626
may	O
occur	O
with	O
intravenous	O
IgG	I:C0020852
as	O
well	O
.	O

Renal	O
adverse	O
effects	I:C0879626
may	O
occur	O
with	O
intravenous	B:C0020852
IgG	I:C0020852
as	O
well	O
.	O

The	O
variety	O
of	O
immunoglobulin	B:C0020852
G	I:C0020852
products	O
and	O
routes	O
of	O
administration	O
available	O
today	O
creates	O
many	O
opportunities	O
for	O
physicians	O
to	O
work	O
with	O
patients	O
to	O
find	O
the	O
optimal	O
therapy	O
for	O
all	O
.	O

The	O
variety	O
of	O
immunoglobulin	O
G	I:C0020852
products	O
and	O
routes	O
of	O
administration	O
available	O
today	O
creates	O
many	O
opportunities	O
for	O
physicians	B:C0031831
to	O
work	O
with	O
patients	O
to	O
find	O
the	O
optimal	O
therapy	O
for	O
all	O
.	O

The	O
variety	O
of	O
immunoglobulin	O
G	I:C0020852
products	O
and	O
routes	O
of	O
administration	O
available	O
today	O
creates	O
many	O
opportunities	O
for	O
physicians	O
to	O
work	O
with	O
patients	O
to	O
find	O
the	O
optimal	O
therapy	B:C0279033
for	O
all	O
.	O

